Literature DB >> 31707542

Leptin: an unappreciated key player in SLE.

Qihang Yuan1, Haifeng Chen2, Xia Li3, Jing Wei4.   

Abstract

Leptin is the forerunner of the adipokine superfamily and plays a key role in regulating energy expenditure and neuroendocrine function. Researches into leptin put emphasize not only on the metabolic role but also its immunoregulatory effect on immune response through immunocyte activation and cytokine secretion. Leptin acts on receptors that are widespread throughout the body and that are expressed across many tissue types. As a consequence, the abnormal expression of leptin has been found to correlate with a number of diseases, including cancers, autoimmune diseases, and cardiovascular diseases. The significance of leptin in the development of autoimmune diseases is becoming increasingly prominent. Systemic lupus erythematosus (SLE) is a severe atypical autoimmune disease that causes damage to multiple organ systems. It is characterised by the following: impaired clearance of apoptotic cells, loss of tolerance to self-antigens, aberrant activation of T cells and B cells, and chronic inflammation. The heightened immunocyte response in SLE means that these physiological systems are particularly vulnerable to regulation by leptin in addition to being of great significance to the research field. Our current review provides insight into the regulatory roles that leptin plays on immune effector cells in SLE.

Entities:  

Keywords:  Immunocytes; Leptin; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2019        PMID: 31707542     DOI: 10.1007/s10067-019-04831-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  131 in total

Review 1.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

2.  A novel leptin receptor antagonist uncouples leptin's metabolic and immune functions.

Authors:  Lennart Zabeau; Joris Wauman; Julie Dam; Sandra Van Lint; Elianne Burg; Jennifer De Geest; Elke Rogge; Anisia Silva; Ralf Jockers; Jan Tavernier
Journal:  Cell Mol Life Sci       Date:  2019-01-18       Impact factor: 9.261

3.  Body composition, insulin, and leptin levels in patients with ankylosing spondylitis.

Authors:  Ismail Sari; Tevfik Demir; Leyla Didem Kozaci; Servet Akar; Tulay Kavak; Merih Birlik; Fatos Onen; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2007-01-27       Impact factor: 2.980

Review 4.  Therapeutic advances in the treatment of SLE.

Authors:  Ali Mohamed; Yongjian Chen; Haijing Wu; Jieyue Liao; Bo Cheng; Qianjin Lu
Journal:  Int Immunopharmacol       Date:  2019-04-16       Impact factor: 4.932

Review 5.  Leptin in autoimmune mechanisms of systemic rheumatic diseases.

Authors:  Luca Navarini; Domenico Paolo Emanuele Margiotta; Marta Vadacca; Antonella Afeltra
Journal:  Cancer Lett       Date:  2018-03-13       Impact factor: 8.679

6.  The impact of obesity on SLE disease activity: findings from the Southern California Lupus Registry (SCOLR).

Authors:  Phildrich Teh; Bishoy Zakhary; Vaneet K Sandhu
Journal:  Clin Rheumatol       Date:  2018-10-24       Impact factor: 2.980

Review 7.  The role of innate immunity in the induction of autoimmunity.

Authors:  David S Pisetsky
Journal:  Autoimmun Rev       Date:  2008-08-15       Impact factor: 9.754

Review 8.  Systemic lupus erythematosus and ocular involvement: an overview.

Authors:  Rosanna Dammacco
Journal:  Clin Exp Med       Date:  2017-12-14       Impact factor: 3.984

Review 9.  Association between leptin and systemic lupus erythematosus.

Authors:  Wang-Dong Xu; Min Zhang; Yu-Jing Zhang; Shan-Shan Liu; Hai-Feng Pan; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2013-05-11       Impact factor: 2.631

10.  Serum levels of adiponectin and leptin as biomarkers of proteinuria in lupus nephritis.

Authors:  Valeria Diaz-Rizo; David Bonilla-Lara; Laura Gonzalez-Lopez; Dalia Sanchez-Mosco; Nicte S Fajardo-Robledo; Edsaul E Perez-Guerrero; N Alejandra Rodriguez-Jimenez; A Miriam Saldaña-Cruz; M Luisa Vazquez-Villegas; Eduardo Gomez-Bañuelos; Monica Vazquez-Del Mercado; E German Cardona-Muñoz; David Cardona-Muller; Xochitl Trujillo; Miguel Huerta; Mario Salazar-Paramo; Jorge I Gamez-Nava
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

View more
  5 in total

1.  QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.

Authors:  Shuo-Lin Wang; Wei Li; Tian-Fang Li; Xu Liang; Ye-Lan Yan; Sheng-Yun Liu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 2.  IFN-I Mediates Dysfunction of Endothelial Progenitor Cells in Atherosclerosis of Systemic Lupus Erythematosus.

Authors:  Xuewei Ding; Wei Xiang; Xiaojie He
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

Review 3.  The Important Role of Leptin in Modulating the Risk of Dermatological Diseases.

Authors:  Xin Su; Ye Cheng; Dong Chang
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

4.  The Adjuvants Polyphosphazene (PCEP) and a Combination of Curdlan Plus Leptin Promote a Th17-Type Immune Response to an Intramuscular Vaccine in Mice.

Authors:  Alyssa Chaffey; Glenn Hamonic; Dylan Chand; George K Mutwiri; Heather L Wilson
Journal:  Vaccines (Basel)       Date:  2021-05-14

Review 5.  The role of leptin in selected skin diseases.

Authors:  Klaudia Dopytalska; Agnieszka Baranowska-Bik; Marek Roszkiewicz; Wojciech Bik; Irena Walecka
Journal:  Lipids Health Dis       Date:  2020-10-02       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.